No Data
No Data
AstraZeneca's COVID-19 Prevention Drug For Patients With Weak Immune Systems - European Medicines Agency Accepts Marketing Application Under Accelerated Assessment
The European Medicines Agency (EMA) has accepted AstraZeneca Plc's (NASDAQ:AZN) marketing authorization application for sipavibart for pre-exposure prophylaxis (prevention) of COVID-19 in immunocompro
AstraZeneca Shares Update and Global Reach
Express News | AstraZeneca's Marketing Authorization Application For Sipavibart Has Been Accepted Under An Accelerated Assessment Procedure By The European Medicines Agency, For The Pre-exposure Prophylaxis (Prevention) Of Covid-19 In Immunocompromised Patients
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application
AstraZeneca (AZN.L, AZN.ST) said Monday that the European Medicines Agency's Committee for Medicinal products for Human Use recommended for approval its combination formulation of Imfinzi and Lynparza
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU
AstraZeneca (AZN.L, AZN.ST) on Monday said the European Medicines Agency accepted its marketing authorization application for its COVID-19 prevention antibody sipavibart under an accelerated assessmen
AstraZeneca: CHMP Recommends Lynparza And Imfinzi Combination For EU Approval In Endometrial Cancer